0001012975-20-000267.txt : 20200227
0001012975-20-000267.hdr.sgml : 20200227
20200227195112
ACCESSION NUMBER: 0001012975-20-000267
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200225
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P.
CENTRAL INDEX KEY: 0001634632
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 20664977
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic GP II, L.P.
CENTRAL INDEX KEY: 0001729409
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 20664978
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic GP II, Ltd.
CENTRAL INDEX KEY: 0001729408
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 20664979
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adelman Robert J
CENTRAL INDEX KEY: 0001329161
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 20664980
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOODMAN COREY S
CENTRAL INDEX KEY: 0001278411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 20664981
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-02-25
0001744659
Akero Therapeutics, Inc.
AKRO
0001634632
venBio Global Strategic Fund II L.P.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO
CA
94158
0
0
1
0
0001729409
venBio Global Strategic GP II, L.P.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO
CA
94158
0
0
1
0
0001729408
venBio Global Strategic GP II, Ltd.
1700 OWENS STREET, SUITE 595
SAN FRANCISCO
CA
94158
0
0
1
0
0001329161
Adelman Robert J
1700 OWENS STREET, SUITE 595
SAN FRANCISCO
CA
94158
0
0
1
0
0001278411
GOODMAN COREY S
1700 OWENS STREET, SUITE 595
SAN FRANCISCO
CA
94158
0
0
1
0
Common Stock
2020-02-25
4
S
0
1600
23.6725
D
3232071
I
See footnote
Common Stock
2020-02-26
4
S
0
2523
22.4397
D
3229548
I
See footnote
Common Stock
2020-02-27
4
S
0
1781
22.54
D
3227767
I
See footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $24.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $22.70, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.40 to $22.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
2020-02-27
venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact
2020-02-27
venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact
2020-02-27
Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact
2020-02-27
Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact
2020-02-27